MatchMedi
한국어

Research record

PD-1 inhibitors: nivolumab and pembrolizumab

PD-1 inhibitors are immune checkpoint drugs. They are not MEK inhibitors, and prior PD-1/PD-L1 failure changes later treatment discussions.

What this is

PD-1 inhibitors are immune checkpoint drugs. They are not MEK inhibitors, and prior PD-1/PD-L1 failure changes later treatment discussions.

Why it may come up

  • adjuvant
  • cannot be removed by surgery
  • has spread
  • depends on treatments already tried

What not to assume

  • No claim that every patient responds.
  • No immune-related adverse-event management instructions beyond ask-your-team prompts.

At a glance

PD-1 inhibitors: nivolumab and pembrolizumab

Used in care guidelinesThis is a commonly recognized treatment category.
Type
Immunotherapy
Mutation result
BRAF, NRAS, KIT, NF1, NTRK, wild-type
Where
US, Korea, Japan, China, EU
Evidence status
guideline-category
Last checked
2026-05-20

What we know

  • NCI PDQ and NCI drug pages support U.S. melanoma drug context.
  • KCIC Korean page explicitly names pembrolizumab and nivolumab as PD-1 inhibitors.
  • Japan sources require more formal PMDA label mapping before making country-specific patient claims.

What is unclear

  • No claim that every patient responds.
  • No immune-related adverse-event management instructions beyond ask-your-team prompts.

Questions to ask

  • Is immunotherapy being used before surgery, after surgery, or for has spread disease?
  • What side effects should trigger a call to the team?
  • If PD-1/PD-L1 therapy already failed, what changes in the next-line plan?

Related cohort stories